Today's Issue

Main Topic: The top 5 pharmaceutical companies by market capitalization - what they make, why they're so valuable, and how they dominate global healthcare

Subtitles:

• The rankings: top 5 pharma companies by market cap (2024)

• #1: Eli Lilly - the Ozempic competitor worth $700+ billion

• #2: Novo Nordisk - the GLP-1 king controlling weight-loss drugs

• #3: Johnson & Johnson - the diversified giant that split in two

• #4: Merck - the cancer immunotherapy powerhouse

• #5: AbbVie - Humira's successor drugs and the biosimilar challenge

Abstract: The top 5 pharmaceutical companies by market capitalization (December 2024) are Eli Lilly ($720 billion), Novo Nordisk ($460 billion), Johnson & Johnson ($380 billion), Merck ($280 billion), and AbbVie ($310 billion), collectively worth $2.15 trillion driven primarily by GLP-1 weight-loss/diabetes drugs (Eli Lilly's Mounjaro/Zepbound generating $13.8 billion in 2024, Novo Nordisk's Ozempic/Wegovy generating $22 billion), cancer immunotherapy checkpoint inhibitors (Merck's Keytruda generating $25 billion annually becoming highest-revenue drug globally), and autoimmune biologics (AbbVie's Humira generating $20 billion before biosimilar competition, replaced by Skyrizi/Rinvoq generating $14 billion). Eli Lilly's valuation tripled 2022-2024 as Mounjaro (tirzepatide, dual GIP/GLP-1 agonist) demonstrated superior weight loss (22.5% body weight reduction vs 15% for Ozempic) creating $100+ billion addressable market for obesity treatment reaching 40% of US adults. Novo Nordisk dominates diabetes (controlling 50%+ global insulin market) and pioneered GLP-1 class with semaglutide (Ozempic/Wegovy) though manufacturing constraints limit supply. Johnson & Johnson spun off consumer health division Kenvue (2023) focusing on pharmaceuticals and medical devices, with key drugs including Darzalex (multiple myeloma, $9 billion), Stelara (autoimmune diseases, $10 billion), and Tremfya (psoriasis). Merck's dominance stems from Keytruda (pembrolizumab) treating 20+ cancer types with patent protection until 2028, while AbbVie transitions from Humira (lost US exclusivity 2023) to next-generation immunology drugs avoiding TNF-alpha mechanism facing biosimilar erosion.

Lose Up to 23% Body Weight

MedVi’s GLP-1 treatments are clinically proven to help patients lose up to 23% of their body weight. Get personalized medical support, proven medications, and a plan designed to deliver real, lasting results.

Start Now for $179

_{Read all warnings before using GLP-ls. Side-effects may include a risk of thyroid c-cell tumors. Do not use GLP-1s if you or your family have a history of thyroid cancer. In certain situations, where clinically appropriate, a provider may prescribe compounded medication, which is prepared by a state-licensed sterile compounding pharmacy partner. Although compounded drugs are permitted to be prescribed under federal law, they are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality.}

#1: Eli Lilly - The Ozempic Competitor Worth $700+ Billion 🏆💊

Flagship drugs:

Mounjaro (tirzepatide for type 2 diabetes): Approved May 2022. Generated $5.8 billion in 2024, growing 300%+ year-over-year. Weekly injection demonstrating 12-22% weight loss in addition to blood sugar control.

Zepbound (tirzepatide for obesity): Approved November 2023. Generated $2.8 billion in first year. Same molecule as Mounjaro but marketed specifically for weight loss in patients without diabetes.

Trulicity (dulaglutide, older GLP-1): $7.4 billion annually, declining as patients switch to more effective Mounjaro.

Verzenio (breast cancer treatment): $4 billion annually, growing 20%+ as expanded indications approved.

Jardiance (diabetes SGLT2 inhibitor): $3.2 billion annually, also shows cardiovascular benefits.

Why Lilly is so valuable:

Superior efficacy: Mounjaro clinical trials showed 22.5% average weight loss (some patients lost 25%+) versus Ozempic's 15% weight loss. This superiority drove doctors and patients to preferentially choose Mounjaro despite being newer to market.

Dual mechanism: Tirzepatide activates both GLP-1 and GIP receptors (glucose-dependent insulinotropic polypeptide), while Ozempic only activates GLP-1. The dual action produces greater weight loss and blood sugar control.

Manufacturing capacity: Lilly invested $18+ billion in new manufacturing facilities (Indiana, North Carolina, Ireland, Germany) specifically for tirzepatide production, positioning to capture demand that Novo Nordisk cannot meet due to supply constraints.

Patent timeline: Mounjaro/Zepbound protected until 2040s, giving Lilly 15-20 years of exclusivity to dominate before biosimilars threaten.

Pipeline strength:

Orforglipron: Oral GLP-1 pill (currently injectable) showing 15% weight loss in Phase 2 trials. Could expand market to patients unwilling to inject weekly.

Retatrutide: Triple hormone agonist (GLP-1, GIP, glucagon) showing 24% weight loss in Phase 2 trials - potentially superior to Mounjaro.

Donanemab: Alzheimer's drug approved July 2024, though commercial success uncertain given modest efficacy and high cost.

#2: Novo Nordisk - The GLP-1 King Controlling Weight-Loss Drugs 👑💉

Flagship drugs:

Ozempic (semaglutide for type 2 diabetes): Approved 2017. Generates $14 billion annually. Weekly injection became cultural phenomenon through social media and celebrity use despite being indicated only for diabetes.

Wegovy (semaglutide for obesity): Approved 2021. Generates $4.5 billion annually, constrained by manufacturing limits. Same molecule as Ozempic, higher dose, marketed specifically for weight loss.

Insulin portfolio: Tresiba (long-acting), Levemir, NovoLog (rapid-acting), NovoRapid generating $8 billion combined. Novo controls 50%+ of global insulin market.

Victoza/Saxenda (liraglutide, older GLP-1): $4 billion annually, declining as patients switch to more effective semaglutide.

Why Novo is so valuable:

Pioneered GLP-1 class: Novo developed first GLP-1 drugs (Victoza 2010, Ozempic 2017, Wegovy 2021), establishing brand dominance and clinical evidence base before competitors entered market.

Cardiovascular benefit: SELECT trial (2023) demonstrated Wegovy reduces cardiovascular events (heart attack, stroke) by 20% in obese patients, expanding insurance coverage beyond cosmetic weight loss to medical necessity.

Insulin monopoly: Controlling half the global insulin market provides steady $8 billion annual revenue base, diversifying beyond GLP-1 dependence.

Brand recognition: "Ozempic" became household name through aggressive marketing and social media virality, creating consumer demand that drives prescriptions.

The manufacturing crisis:

Novo cannot produce enough Ozempic/Wegovy to meet demand, creating 12-24 month waitlists at pharmacies. This supply constraint limits revenue growth and allows competitors (Lilly, Amgen, Pfizer) to capture market share.

Novo invested $6 billion expanding Danish and US manufacturing facilities, but new capacity won't come online until 2025-2026.

Patent timeline: Semaglutide protected until 2031-2033 depending on jurisdiction, giving Novo 7-9 years remaining exclusivity before biosimilars threaten.

Pipeline:

CagriSema: Combination of semaglutide and cagrilintide (amylin agonist) showing 25% weight loss in Phase 2 trials - potentially superior to Mounjaro.

Once-monthly GLP-1: Icodec showing similar efficacy with monthly dosing, improving convenience.

#3: Johnson & Johnson - The Diversified Giant That Split in Two 🏥🔬

Flagship pharmaceutical drugs:

Darzalex (daratumumab for multiple myeloma): $9.5 billion annually, growing 20%+. Monoclonal antibody targeting CD38 on cancer cells. Combination with chemotherapy became standard care.

Stelara (ustekinumab for Crohn's disease, ulcerative colitis, psoriasis): $10 billion in 2023, declining as biosimilars launch following patent expiration. IL-12/IL-23 inhibitor, once J&J's top drug.

Tremfya (guselkumab for psoriasis, psoriatic arthritis): $3.5 billion annually, growing 30%+. IL-23 inhibitor replacing Stelara as it loses exclusivity.

Imbruvica (ibrutinib for blood cancers): $4 billion annually (split with AbbVie partnership). BTK inhibitor for chronic lymphocytic leukemia and lymphomas.

Erleada (apalutamide for prostate cancer): $2.2 billion annually, growing 25%+.

Strengths:

Diversification reduces risk: Unlike Merck (40%+ revenue from Keytruda) or AbbVie (formerly 50%+ from Humira), J&J spreads revenue across 10+ drugs and medical devices, protecting against patent cliffs.

Strong oncology pipeline: Multiple cancer drugs in development, positioning for continued growth as Darzalex eventually faces biosimilar competition.

Decades of operational excellence: J&J consistently ranks among most admired companies, with strong R&D productivity and commercial execution.

Challenges:

Multiple patent cliffs: Stelara lost exclusivity 2023, Imbruvica faces generic competition 2026-2027, Darzalex protected until 2030s. Replacing $15+ billion in declining revenue requires pipeline success.

Limited obesity exposure: No GLP-1 drugs in portfolio, missing explosive growth category driving Lilly and Novo valuations.

Talc litigation overhang: Thousands of lawsuits alleging baby powder caused cancer, with billions in potential liabilities creating investor uncertainty.

#4: Merck - The Cancer Immunotherapy Powerhouse 🎯🔬

Flagship drug - Keytruda dominance:

Keytruda (pembrolizumab) generates $25 billion annually, making it the highest-revenue pharmaceutical drug globally. Checkpoint inhibitor blocking PD-1 receptor, approved for 20+ cancer types including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, bladder cancer, kidney cancer, gastric cancer, cervical cancer, liver cancer, esophageal cancer.

Why Keytruda dominates:

First-mover advantage: Approved 2014 as first PD-1 inhibitor, accumulating years more clinical data than competitors (Opdivo, Tecentriq, Libtayo), making doctors comfortable prescribing it.

Combination therapies: Keytruda combined with chemotherapy shows superior efficacy versus chemotherapy alone, making it standard first-line treatment for many cancers.

Earlier-stage expansion: Originally approved for metastatic (late-stage) cancer, now approved for earlier-stage disease and adjuvant therapy (after surgery to prevent recurrence), expanding patient population.

Other significant drugs:

Gardasil/Gardasil 9 (HPV vaccine): $9.5 billion annually. Prevents cervical cancer, throat cancer, genital warts caused by human papillomavirus. Growing in emerging markets.

Januvia/Janumet (diabetes DPP-4 inhibitors): $4 billion annually, declining as GLP-1s prove superior.

Lynparza (ovarian/breast cancer PARP inhibitor): Partnership with AstraZeneca, $2.5 billion Merck share.

Pipeline strategy:

Merck investing heavily in Keytruda combinations (with chemotherapy, with other immunotherapies, with targeted therapies) and earlier-stage cancer vaccines to extend Keytruda franchise beyond 2028. Success uncertain.

#5: AbbVie - Humira's Successor Drugs and the Biosimilar Challenge 💊📉

The Humira story:

Humira (adalimumab) was the highest-revenue drug in pharmaceutical history, generating $20+ billion annually at peak (2018-2022). TNF-alpha blocker treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, ankylosing spondylitis.

Lost US patent exclusivity January 2023, triggering biosimilar competition from Amjevita, Hadlima, Cyltezo, Hyrimoz, Yuflyma, Abrilada (6+ competitors).

Humira revenue collapsed from $21 billion (2022) to $8 billion (2024) as biosimilars captured 60%+ market share through 30-50% discounts.

International revenue declining similarly as European patents expire.

The succession strategy:

AbbVie spent decade developing next-generation immunology drugs using different mechanisms to avoid biosimilar competition:

Skyrizi (risankizumab, IL-23 inhibitor): $7.8 billion in 2024, growing 50%+ annually. Treats psoriasis, psoriatic arthritis, Crohn's disease. Superior efficacy to Humira in head-to-head trials, dosed every 12 weeks versus Humira's every 2 weeks, improving patient compliance.

Rinvoq (upadacitinib, JAK inhibitor): $4.4 billion in 2024, growing 60%+ annually. Treats rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, atopic dermatitis. Oral pill versus Humira's injection, appealing to needle-averse patients. FDA added black box warnings for blood clots and infections, slowing but not stopping growth.

The transition challenge:

AbbVie must replace Humira's $20+ billion peak revenue with Skyrizi/Rinvoq growth. Current trajectory suggests $15+ billion combined by 2027, partially filling gap. However, total company revenue declining 2023-2025 during transition, creating investor uncertainty.

Other drugs providing diversification:

Imbruvica (blood cancer): Partnership with J&J, $4 billion AbbVie share, declining as newer BTK inhibitors launch.

Botox (medical and cosmetic): $5 billion annually. Treats chronic migraines, overactive bladder, muscle spasticity, plus cosmetic wrinkles. Stable revenue, minimal competition.

Venclexta (blood cancer BCL-2 inhibitor): $3 billion annually, growing.

The Proven System Fitness Instructors Use to Grow Online

Discover Kajabi’s 30 Days to Launch: Scale Your Fitness Business Online guide. Launch online programs, memberships, and digital products while keeping in-person clients. Step-by-step roadmap, success stories, and AI prompts included.

🚀 Get the Free Guide

Takeaways

• Top 5 pharmaceutical companies (Eli Lilly $720B, Novo Nordisk $460B, Johnson & Johnson $380B, AbbVie $310B, Merck $280B) collectively worth $2.15 trillion, with rankings dominated by GLP-1 weight-loss/diabetes drugs (Lilly's Mounjaro/Zepbound $13.8B, Novo's Ozempic/Wegovy $22B) and cancer immunotherapy (Merck's Keytruda $25B becoming highest-revenue drug globally).

• Eli Lilly's valuation tripled 2022-2024 as Mounjaro demonstrated superior 22.5% weight loss versus Ozempic's 15%, capturing explosive $100+ billion obesity treatment market reaching 40% of US adults, while Novo Nordisk faces manufacturing constraints limiting ability to meet demand despite pioneering GLP-1 class and controlling 50%+ global insulin market.

• Traditional pharma giants face patent cliffs and strategic transitions: Johnson & Johnson spun off consumer division Kenvue (2023) focusing on pharmaceuticals/devices, Merck depends on Keytruda for 40%+ revenue (patent expires 2028), AbbVie replacing Humira ($20B peak, now $8B with biosimilars) with next-generation Skyrizi/Rinvoq ($14B growing 50-60% annually) requiring successful pipeline execution maintaining market dominance.

Feeling Anxious? You are not alone

Get help from a licensed therapist - anytime, anywhere. BetterHelp has helped over 5 million people, with no commitment, 100% online.

Take the first step, with 25% off your first month, and a network of 30,000 therapists to choose from. BetterHelp therapy is HSA + FSA eligible. Just take our quiz to get matched with a therapist and start your journey.

GET 25% OFF TODAY

_{This email was delivered by a third-party, on behalf of BetterHelp. Copyright © 2025 BetterHelp. All Rights Reserved. 990 Villa St, Mountain View, California, United States.}